Microsoft Joins Forces with AMD to Power Future of Xbox Across Devices
June 18 - Microsoft (NASDAQ:MSFT) and Advanced Micro Devices (NASDAQ:AMD) have entered a multi-year collaboration to jointly develop custom chips for a range of devices, including the next wave of Xbox consoles, according to a Tuesday press release.
The companies plan to co-engineer silicon to power a broader gaming ecosystem, spanning traditional consoles to handheld devices. The partnership builds on their prior work, with AMD having supplied chips for earlier Xbox and PlayStation models.
Warning! GuruFocus has detected 6 Warning Sign with MSFT.
Xbox president Sarah Bond said the next-generation Xbox will support a flexible hardware lineup and won't be limited to a single game store. She emphasized that the aim is to offer a seamless experience across devices while preserving backward compatibility with existing Xbox games.
Microsoft recently introduced the Xbox Ally and Ally X handhelds, developed with ASUS, with a release expected later this fall. The new devices allow access to the Xbox library on the go and support cloud gaming.
The moves are part of Microsoft's strategy to broaden its gaming reach beyond consoles, with a stronger focus on Game Pass and cloud-based services.
The company has also expanded game access to competing platforms and is working to open its devices to third-party stores, starting with its Ally line.
Microsoft's gaming revenue, housed under its More Personal Computing segment, totaled $13.37 billion in the third quarter, with Xbox content and services growing 8% year over year.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Nvidia (NVDA) Target Raised to $200 by Barclays Amid Blackwell Ramp, AI Cloud Expansion
Nvidia (NVDA, Financials) received a price target upgrade from Barclays on Monday, with analysts citing stronger-than-expected Compute segment growth and expanding Blackwell chip production. Warning! GuruFocus has detected 4 Warning Signs with NVDA. Barclays raised its target to $200 from $170 and maintained an Overweight rating, forecasting Nvidia will beat consensus revenue estimates by $2 billion for the July quarter. The firm now expects Q3 revenue to reach $42 billion and Q4 to hit $48 billion, compared to Wall Street's estimates of $40.8 billion and $46.2 billion, respectively. The revision comes as Blackwell chip production scales, reaching 30,000 wafers per month in June. Though below the firm's earlier forecast of 40,000, Barclays said utilization rates remain healthy and expects ramped system sales to comprise nearly half of total revenue by October. The forecast boost aligns with positive supply chain feedback and accelerating enterprise AI demand. Nvidia's collaboration with Deutsche Telekom to build Europe's first industrial AI cloud also signals geographic expansion. The project involves 10,000 chips from Nvidia and is expected to complete by 2026. Nvidia is excluding China from revenue guidance amid U.S. restrictions, CEO Jensen Huang confirmed. Competitors like Advanced Micro Devices (AMD, Financials) are stepping up AI chip efforts, with new MI350 and MI400 series launches, but analysts suggest Nvidia's ecosystem remains dominant. Investors should monitor upcoming Blackwell Ultra volumes and progress on European cloud deployments for near-term catalysts. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fast Company
an hour ago
- Fast Company
Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut
On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq's opening bell in New York, marking the company's awaited initial public offering. The diagnostics company's IPO follows the successful debut of fintech companies like Chime Financial and Circle Internet Group, and will test whether investors are ready to embrace biotech companies despite declines in the sector for the last six months. Here's what to know about the listing. What is Caris Life Sciences? Founded in 2008 by David Dean Halbert, the healthcare company utilizes next-generation artificial intelligence (AI) and machine learning for precision medicine. Through molecular analysis, Caris specializes in cancer diagnosis and treatment. According to a recent filing to the Securities and Exchange Commission (SEC), the Irving, Texas-based company currently has over 1,700 employees and over 100 biopharmaceutical partners. The company incurred net losses of $281.9 million and $341.4 million in 2024 and 2023, respectively, on revenue of $412.3 million and $306.1 million. It is expecting additional losses in the future. When is Caris Life Sciences's IPO? Caris Life Sciences shares are expected to begin trading on Wednesday, June 18, with the offering expected to run through June 20. What is Caris Life Sciences's stock ticker? Caris Life Sciences will trade its stock under the ticker CAI. What is the IPO price for CAI? CAI shares were priced at $21, above their previously planned range. The IPO price was planned between the $19 and $20 range, up from the previous $16 and $18 planned price. The current pricing would value Caris Life Sciences at around $5.9 billion. What exchange will the stock trade in? CAI will trade its shared on the Nasdaq Global Select Market.
Yahoo
an hour ago
- Yahoo
Goldman Sachs Recommends Buying Apple, Expects Stock to Climb
Apple Inc. (NASDAQ:AAPL) is one of the . An Apple store displaying the latest in consumer electronics, from smartphones to wearables. Goldman Sachs recently highlighted a group of stocks that its analysts believe still have significant growth potential. The firm views these companies as resilient and recommends that investors act quickly to buy them, with Apple Inc. (NASDAQ:AAPL) being one of the top picks on the list. The firm made the following comment: 'We are Buy-rated on AAPL as we believe that the market's focus on slower product revenue growth masks the strength of the AAPL ecosystem & associated revenue durability & visibility. … .Valuation is attractive relative to AAPL's historical multiple — both on an absolute & relative basis — and compared to key tech peers.' Apple Inc. (NASDAQ:AAPL) is not only a tech giant but also a very solid dividend payer. The stock's dividend yield may be low at 0.52%, but it maintains a 13-year streak of dividend growth. While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
